Physician profile
Bethany A Wait
NPI 1447458096
$1,753.70
in general payments reported to CMS, 2019-2025
23 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.52 · 2021: $75.25 · 2022: $354 · 2023: $374 · 2024: $500 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.02 | 2022-2025 | Vraylar, Ubrelvy |
| Dexcom, INC. | $110.69 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $108.88 | 2023-2025 | Omnipod |
| Gilead Sciences, INC. | $101.08 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.42 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $69.86 | 2019-2025 | Bexsero, Penmenvy, Rotarix |
| Welch Allyn | $63.33 | 2021 | |
| Novo Nordisk INC | $62.44 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $51.31 | 2023-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $46.62 | 2021-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Pfizer INC. | $45.05 | 2024-2025 | |
| Alkermes, INC. | $36.69 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Medline Industries LP | $34.77 | 2022 | |
| Indivior INC. | $26.20 | 2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $19.80 | 2025 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $17.39 | 2022 | |
| Philips North America LLC | $16.96 | 2024 | (Ck7) Extended Holter |
| Amgen INC. | $16.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.20 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $15.19 | 2023 | |
| Exact Sciences Corporation | $13.99 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $11.80 | 2019 | |
| Sanofi Pasteur INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Wait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.